Coupa Achieves ISO 27001 Certification SAN MATEO, Calif.,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
83
Coupa Achieves ISO 27001 Certification

SAN MATEO, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coupa Software (NASDAQ: COUP ), a leader in cloud-based spend management, today announced that it has obtained ISO 27001 certification for its information security management system supporting the Coupa spend management cloud. The certification was performed by Schellman , an ANAB and UKAS Accredited Certification Body based in the United States.

Schellman certified Coupa as compliant with all of the ISO/IEC 27001:2013 certification requirements - the international standard from the International Organization for Standardization (ISO) and the International Electrotechnical Commission . ISO 27001 is a globally recognized standard for the establishment, maintenance, and certification of an information security management system (ISMS). The details of Coupa’s ISO 27001 ISMS certification are publicly available in the Schellmann Certificate Directory.                                                             “Coupa is committed to providing independent assurance of our security controls and practices through third-party audits and certifications such as SSAE 16 and ISO 27001,“ said Phil Cox, vice president of security and compliance for Coupa. “Obtaining ISO 27001 certification is a tremendous achievement, as we continue to provide our customers with confidence that our security controls and practices follow internationally recognized security standards.”     

The ISO 27001 standard specifies the requirements for establishing, implementing, operating, monitoring, reviewing, maintaining and improving a documented ISMS within the context of the organization’s overall business risks. It sets forth a risk-based approach that focuses on adequate and proportionate security controls that protect information assets and give confidence to interested parties.                                 Schellman & Company, LLC (Schellman) is a leading provider of attestation and compliance services. Schellman is the only company in the world that is a CPA firm, a globally licensed PCI Qualified Security Assessor, an ISO Certification Body, HITRUST CSF Assessor, and a FedRAMP 3PAO. Renowned for expertise tempered by practical experience, Schellman's professionals provide superior client service balanced by steadfast independence. The Schellman approach builds successful, long-term relationships and allows its clients to achieve multiple compliance objectives through a single third party assessor.

Born in the cloud, Coupa delivers a modern spend management platform that accelerates business by unifying processes across all the ways employees spend money. These processes cover travel and expense management, procurement, invoicing and related source-to-settle areas. Using the Coupa Open Business Network, the platform has connected more than 2 million suppliers and delivers a powerful solution for businesses committed to controlling their spend.

About Coupa Software Coupa Software (NASDAQ: COUP ) is the cloud platform for business spend. We deliver “Value as a Service” by helping our customers maximize their spend under management, achieve significant cost savings and drive profitability.  Coupa provides a unified, cloud-based spend management platform that connects hundreds of organizations representing the Americas, EMEA, and APAC with millions of suppliers globally.  The Coupa platform provides greater visibility into and control over how companies spend money. Customers – small, medium and large – have used the Coupa platform to bring billions of dollars in cumulative spend under management.  Learn more at www.coupa.com . Read more on the Coupa Blog or follow @Coupa on Twitter .

Media inquiries: Orlando De Bruce Coupa Software            Global Public Relations orlando.debruce@coupa.com O (650) 485-8629

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Therapeutics Gains Confidence with Strategic Developments

Updated Category News Views 60

Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...

Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy

Updated Category News Views 167

Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...

Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids

Updated Category News Views 17

Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...

Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch

Updated Category News Views 147

Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...

Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth

Updated Category News Views 229

Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...

Continue Reading